10-Q · May 14, 2026
Pyxis Oncology (PYXS) reported a disappointing Q1 2026, with no revenue and a diluted EPS of -$0.37, missing expectations. The company continues to focus on its clinical pipeline, particularly the MICVO product…
Earnings analysis · 10-Q
PYXS earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The 10-Q portrays a clinical-stage company with no product-sales revenue disclosed in the filing excerpt, substantial ongoing losses and a material funding gap. Six-month net loss widened to $48.6 million from $39.5…
Read full summary
The 10-Q portrays a clinical-stage company with no product-sales revenue disclosed in the filing excerpt, substantial ongoing losses and a material funding gap. Six-month net loss widened to $48.6 million from $39.5 million, and management states that approximately $34.5 million of liquidity at June 30, 2026, even after the approximately $50 million financing, will not fund operations for the next 12 months. The financing supports MICVO development but introduces dilution through 19,600,153 shares and warrants representing approximately $64.0 million of potential additional proceeds.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Losses Continue to Widen
Six-month net loss increased to $48.6 million from $39.5 million in the prior-year period, while accumulated deficit reached $491.8 million as of June 30, 2026.
-
$50M Financing Extends Liquidity
The company had approximately $34.5 million in cash, cash equivalents, restricted cash and marketable debt securities at June 30, 2026, and subsequently received approximately $50 million of gross private-placement proceeds on July 2, 2026.
-
Additional $64M Warrant Upside
The private placement included 19,600,153 common shares priced at $2.551 per share and warrants that could generate approximately $64.0 million of additional gross proceeds if exercised in full.
-
Capital Supports MICVO Development
Management intends to use the financing proceeds for continued advancement of MICVO through key clinical milestones and for working capital and general corporate purposes.
-
Significant Insider Ownership
Executive officers, directors and holders of more than 5% of the common stock beneficially owned approximately 38.1% of outstanding shares, or approximately 57.6% including exercisable options and warrants, as of August 12, 2026.
What to watch
-
Going-Concern and Funding Risk
The filing states that cash and marketable securities, even after the private-placement proceeds, will not be sufficient to fund operations for the next 12 months. The company reported approximately $34.5 million of liquidity at June 30, 2026 and acknowledges substantial doubt about continuing as a going concern.
-
Persistent and Increasing Cash Burn
The company reported six-month net losses of $48.6 million and an accumulated deficit of $491.8 million. Management expects significant expenses and increasing operating losses for at least the next several years.
-
Dilution From Equity Financing
The July 2, 2026 financing issued 19,600,153 shares and warrants for an additional approximately $64.0 million of potential proceeds, creating meaningful dilution risk if warrants are exercised or additional equity is issued.
-
China Supply-Chain Exposure
The filing newly emphasizes risks from manufacturing in China and potential U.S. restrictions on foreign biotechnology or manufacturing service providers. A disruption could accelerate cash burn and increase the need for additional capital.
-
Evolving Regulatory Requirements
The filing adds or expands discussion of evolving oncology dose-optimization requirements, including FDA Project Optimus, which could require additional dose-ranging studies and delay development of MICVO.
-
Emerging AI and Compliance Risk
The company disclosed increased exposure to artificial-intelligence risks, including inaccurate outputs, data-privacy issues, intellectual-property concerns and evolving regulatory requirements; noncompliance could result in delays, increased costs or litigation.
Management's outlook
The 10-Q does not provide numeric revenue or EPS guidance. Management states that cash resources will not be sufficient to fund operations over the next 12 months and that substantial additional funding will be required. The filing also states that Common Warrants become exercisable on or after October 1, 2026, or earlier public disclosure of MICVO Phase 1 monotherapy data.
Earlier filings 4
10-K · March 23, 2026
The 2025 Form 10-K emphasizes strong early clinical signals for lead ADC candidate micvotabart pelidotin (MICVO) — the filing reports a confirmed monotherapy ORR of 46% (6/13) and combination ORR of 71% (5/7) in…
10-Q · August 14, 2025
Pyxis Oncology reported Q2 revenues of $2.82 million (milestone revenue) and GAAP diluted loss per share of $(0.30). R&D spending accelerated to $17.13 million in the quarter while the company used $39.80 million of…
10-K · March 18, 2025
Pyxis is a clinical-stage ADC company prioritizing development of micvotabart pelidotin (formerly PYX-201) after a strong Phase 1 signal in R/M HNSCC (50% ORR in six evaluable patients at active doses). The company has…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.